Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


RedHill Biopharma Ltd.-Product Pipeline Review-2015

RedHill Biopharma Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

RedHill Biopharma Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'RedHill Biopharma Ltd.-Product Pipeline Review-2015', provides an overview of the RedHill Biopharma Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RedHill Biopharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of RedHill Biopharma Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of RedHill Biopharma Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the RedHill Biopharma Ltd.'s pipeline products

Reasons To Buy

Evaluate RedHill Biopharma Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of RedHill Biopharma Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the RedHill Biopharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of RedHill Biopharma Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of RedHill Biopharma Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of RedHill Biopharma Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

RedHill Biopharma Ltd. Snapshot 5

RedHill Biopharma Ltd. Overview 5

Key Information 5

Key Facts 5

RedHill Biopharma Ltd.-Research and Development Overview 6

Key Therapeutic Areas 6

RedHill Biopharma Ltd.-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Combination Treatment Modalities 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

RedHill Biopharma Ltd.-Pipeline Products Glance 13

RedHill Biopharma Ltd.-Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13

Filing rejected/Withdrawn Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

RedHill Biopharma Ltd.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

RedHill Biopharma Ltd.-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

RedHill Biopharma Ltd.-Drug Profiles 19

ondansetron hydrochloride CR 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

rizatriptan benzoate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(rifabutin + amoxicillin sodium + omeprazole sodium) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(rifabutin + clarithromycin + clofazimine) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

carvedilol CR 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

upamostat 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ABC-294640 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

RedHill Biopharma Ltd.-Pipeline Analysis 32

RedHill Biopharma Ltd.-Pipeline Products by Target 32

RedHill Biopharma Ltd.-Pipeline Products by Route of Administration 34

RedHill Biopharma Ltd.-Pipeline Products by Molecule Type 35

RedHill Biopharma Ltd.-Pipeline Products by Mechanism of Action 36

RedHill Biopharma Ltd.-Recent Pipeline Updates 37

RedHill Biopharma Ltd.-Locations And Subsidiaries 47

Head Office 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

RedHill Biopharma Ltd., Key Information 5

RedHill Biopharma Ltd., Key Facts 5

RedHill Biopharma Ltd.-Pipeline by Indication, 2015 7

RedHill Biopharma Ltd.-Pipeline by Stage of Development, 2015 8

RedHill Biopharma Ltd.-Monotherapy Products in Pipeline, 2015 9

RedHill Biopharma Ltd.-Combination Treatment Modalities in Pipeline, 2015 10

RedHill Biopharma Ltd.-Partnered Products in Pipeline, 2015 11

RedHill Biopharma Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 12

RedHill Biopharma Ltd.-Pre-Registration, 2015 13

RedHill Biopharma Ltd.-Filing rejected/Withdrawn, 2015 14

RedHill Biopharma Ltd.-Phase III, 2015 15

RedHill Biopharma Ltd.-Phase II, 2015 16

RedHill Biopharma Ltd.-Phase I, 2015 17

RedHill Biopharma Ltd.-Preclinical, 2015 18

RedHill Biopharma Ltd.-Pipeline by Target, 2015 33

RedHill Biopharma Ltd.-Pipeline by Route of Administration, 2015 34

RedHill Biopharma Ltd.-Pipeline by Molecule Type, 2015 35

RedHill Biopharma Ltd.-Pipeline Products by Mechanism of Action, 2015 36

RedHill Biopharma Ltd.-Recent Pipeline Updates, 2015 37

List of Figures

RedHill Biopharma Ltd.-Pipeline by Top 10 Indication, 2015 6

RedHill Biopharma Ltd.-Pipeline by Stage of Development, 2015 8

RedHill Biopharma Ltd.-Monotherapy Products in Pipeline, 2015 9

RedHill Biopharma Ltd.-Combination Treatment Modalities in Pipeline, 2015 10

RedHill Biopharma Ltd.-Partnered Products in Pipeline, 2015 11

RedHill Biopharma Ltd.-Pipeline by Top 10 Target, 2015 32

RedHill Biopharma Ltd.-Pipeline by Top 10 Route of Administration, 2015 34

RedHill Biopharma Ltd.-Pipeline by Top 10 Molecule Type, 2015 35

RedHill Biopharma Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of RedHill Biopharma Ltd.; RedHill Biopharma Ltd. - Key Therapeutics; RedHill Biopharma Ltd. - Pipeline Overview and Promising Molecules; RedHill Biopharma Ltd. - News; RedHill Biopharma Ltd. - Latest Updates; RedHill Biopharma Ltd. - Pipeline; RedHill Biopharma Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com